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Abstract
Background: Topoisomerase II poisons are in clinical use as anti-cancer therapy for decades and
work by stabilizing the enzyme-induced DNA breaks. In contrast, catalytic inhibitors block the
enzyme before DNA scission. Although several catalytic inhibitors of topoisomerase II have been
described, preclinical concepts for exploiting their anti-proliferative activity based on molecular
characteristics of the tumor cell have only recently started to emerge. Topoisomerase II is an
ATPase and uses the energy derived from ATP hydrolysis to orchestrate the movement of the
DNA double strands along the enzyme. Thus, interfering with ATPase function with low molecular
weight inhibitors that target the nucleotide binding pocket should profoundly affect cells that are
committed to undergo mitosis.
Results: Here we describe the discovery and characterization of a novel purine diamine analogue
as a potent ATP-competitive catalytic inhibitor of topoisomerase II. Quinoline aminopurine
compound 1 (QAP 1) inhibited topoisomerase II ATPase activity and decatenation reaction at sub-
micromolar concentrations, targeted both topoisomerase II alpha and beta in cell free assays and,
using a quantitative cell-based assay and a chromosome segregation assay, displayed catalytic
enzyme inhibition in cells. In agreement with recent hypothesis, we show that BRCA1 mutant
breast cancer cells have increased sensitivity to QAP 1.
Conclusion: The results obtained with QAP 1 demonstrate that potent and selective catalytic
inhibition of human topoisomerase II function with an ATP-competitive inhibitor is feasible. Our
data suggest that further drug discovery efforts on ATP-competitive catalytic inhibitors are
warranted and that such drugs could potentially be developed as anti-cancer therapy for tumors
that bear the appropriate combination of molecular alterations.
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Background
Topoisomerase type II is an ATPase of the GHKL (gyrase,
Hsp90, histidine kinase, MutL)-family that is evolution-
ary conserved in eukaryotes and essential for chromo-
some segregation during mitosis [1]. Mammals express
two topoisomerase type II isoforms, alpha and beta,
which are highly homologous but display differences in
expression and in sub-cellular localization at the time of
mitosis [2]. Like topoisomerases type I and III, the type II
enzyme can remove topological constraints on DNA.
However, it is the only enzyme that is capable of decate-
nating intertwined chromatids. Catenations in sister chro-
matids arise during DNA replication and must be
removed to allow faithful chromosome segregation dur-
ing anaphase [3]. Topoisomerase II is a homodimer that
clamps onto two DNA double strands upon ATP binding
to the amino-terminal ATPase domains. Subsequently,
the enzyme transiently cleaves one of the DNA double
strands and, using the energy derived from ATP hydroly-
sis, transports the second DNA double strand through the
gap. The cleaved strand is rapidly religated and the DNA
strands are released from the enzyme upon hydrolysis of
the second molecule ATP and dissociation of ADP mole-
cules [3,4]. Drugs that interfere with topoisomerase II
function have been developed as antitumor agents and are
in clinical use already for decades [5]. However, the vast
majority of these drugs act by stabilizing the state in which
the enzyme has introduced the DNA double strand break
and induce a so-called cleavable complex [6,7]. Conse-
quently, tumor cell death is triggered by the substantial
DNA damage elicited by the so-called topoisomerase II
poisons. Despite broad antitumor activity, the use of
topoisomerase II poisons as cancer chemotherapy is lim-
ited by a narrow therapeutic window as concomitant
damage to healthy cells and tissues is almost inevitable
[8].
Drugs that inhibit topoisomerase II function without
inducing cleavable complexes are termed catalytic inhibi-
tors [9]. These drugs are thought to impede a step in the
catalytic cycle that precedes DNA double strand scission
and exert their antiproliferative effects by depleting the
essential enzymatic function. Such drugs are thought to
mainly affect cells that are committed to undergo mitosis
and recent data suggest that tumor cells with defects in
certain checkpoint control mechanisms might be particu-
larly sensitive to catalytic inhibitors [10]. It has been pro-
posed that cells employ two distinct checkpoint
mechanisms in G2 and M phase, respectively, in response
to catalytic topoisomerase II inhibition. In the G2 phase of
the cell cycle a "DNA-decatenation checkpoint" is trig-
gered that delays entry of cells into mitosis [11]. This
checkpoint was shown to be caffeine sensitive and
dependent on ATM/ATR (ataxia-telangiectasia mutated/
ATM- and Rad3-related), BRCA1 (breast cancer gene 1)
and the WRN (Werner syndrome gene) helicase [12-14].
Interestingly, in one study it was found that a fraction of
lung cancer cell lines were hypersensitive toward the bis-
dioxopiperazine catalytic topoisomerase II inhibitor
ICRF-193 [13]. The hypersensitive cells failed to activate
ATM and to delay entry into mitosis upon incubation with
ICRF-193. Furthermore, recent evidence suggests that cells
arrest in metaphase upon depletion of topoisomerase II or
treatment with the catalytic inhibitor ICRF-193 [15,16].
The metaphase arrest was shown to be distinct from the
spindle assembly checkpoint but nonetheless to be
dependent on the checkpoint protein Mad2 [15,17].
These data suggest that it may be possible to develop cat-
alytic inhibitors of topoisomerase II as anticancer therapy
to target tumors with the appropriate molecular altera-
tions [10].
The bisdioxopiperazines inhibit the catalytic cycle of
topoisomerase II by binding in proximity of the ATP bind-
ing site and trapping the enzyme as a closed clamp on
DNA [18]. Alternatively, the catalytic cycle can be halted
by drugs that dock into the ATP-binding pocket and pre-
vent nucleotide binding. Drugs that target bacterial DNA-
gyrase were shown to function by this mechanism of
action and have been developed as antibiotics [19]. Nota-
bly, recent data suggest that this approach should also be
applicable to the eukaryotic enzyme [20-22]. Starting
from a homology model derived from DNA-gyrase and
subsequently using the yeast [18] and more recently the
human topoisomerase II ATPase domain crystal structures
[23] we have undertaken structure-based drug discovery
efforts on this exciting target with the aim of identifying
ATP-competitive catalytic inhibitors. Relying on an enzy-
matic ATPase assay, these efforts have led to the discovery
of novel designed purine diamino analogues as potent
ATP-competitive catalytic inhibitors of topoisomerase II.
The quinoline aminopurine 1 (QAP 1) inhibited topoi-
somerase II ATPase activity as well as the decatenation
reaction and targeted both topoisomerase II alpha and
beta isoforms in cell-free assays. Importantly, QAP 1 dis-
played catalytic enzyme inhibition in cells as shown by
antagonism of doxorubicin-induced DNA damage and
aberrant chromosome segregation. Finally, we show that
breast tumor cells with a mutation in BRCA1 have
increased sensitivity towards QAP 1 as compared to cells
reconstituted with BRCA1.
Results
Screening for ATP-competitive Topoisomerase II Inhibitors 
using Molecular Modeling combined with an ATPase Assay
Based on homology structural models of the target, a
purine scaffold was designed interactively using the Mac-
romodel modeling software [24]. The designed purine
scaffold was subsequently used as a substructure query to
search the Novartis compound collection. Around 50BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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molecules were retrieved in this manner and screened in
an ATPase assay using purified full length tagged human
topoisomerase II alpha. Screening this set of compounds
resulted in two micromolar hits that were further opti-
mized by structure-based design (manuscripts in prepara-
tion). Submicromolar activity with an IC50 of 432 ± 30 nM
in the ATPase assay was obtained with the purine ana-
logue 3 that is substituted with an ethyl group at position
C6, a tert-butyl group at position N6 and containing a ben-
zothiazole group in position N2 (manuscripts in prepara-
tion). Introduction of a morpholino-ethoxy group in the
quinoline aminopurine (QAP 1) improved activity in the
ATPase assay to an IC50 of 128 ± 21 nM (Figure 1A, B).
Subsequently, we carried out kinetic analysis with QAP 1
in order to corroborate the mode of action. When the
apparent Km of topoisomerase II for ATP was determined
in the presence of IC50 concentrations of QAP 1 (130 nM)
an increase in the Km from 310 ± 6 nM to 466 ± 84 nM was
observed (Figure 1C). The data were analyzed by non-lin-
ear regression analysis using the equations corresponding
to competitive, uncompetitive, and mixed inhibition (see
Methods) and a statistical analysis (F-test; p ≤ 0.05) was
carried out to identify the best model. These studies
revealed that QAP 1 is an ATP-competitive inhibitor of
topoisomerase II. A linearized representation (Eady-Hofs-
tee) of one of these experiments is depicted in Figure 1D.
To confirm the mode of action of QAP 1, inhibition stud-
ies were also carried out in the presence of different con-
centration of the inhibitor at different ATP concentrations
and the IC50 values were determined. Figure 1E shows
that, according to the Cheng-Prusoff equation for a linear
competitive inhibitor [25], the IC50 of QAP 1 increases in
a linear fashion with increasing ATP concentrations. These
data, together with the results presented in Figure 1D sug-
gest that QAP 1 is an ATP-competitive inhibitor. Next,
QAP 1 was tested against a panel of kinases in a radiomet-
ric assay [26]. With the exception of subtle inhibition of
the Ret and c-Src tyrosine kinases no effect of the com-
pound was observed on other kinases in the panel, even at
the highest concentration tested (Table 1). Thus, QAP 1 is
a relatively potent inhibitor of topoisomerase II ATPase
function with fairly good selectivity over various serine/
threonine/tyrosine protein kinases. To test if QAP 1 inhib-
ited topoisomerase II DNA strand passage activity, nuclear
extracts of HL-60 leukemic cells were incubated with cate-
nated kDNA in the presence of increasing concentrations
of QAP 1. In this functional assay QAP 1 was found to
inhibit DNA decatenation with a mean IC50 of 770 nM
(Figure 1F, G), which was in the range of the values meas-
ured with ICRF-193 [27], a non-ATP competitive catalytic
inhibitor of topoisomerase II and most potent bisdioxopi-
perazine described to date. Similarly, in DNA decatena-
tion assays using the purified human topoisomerase II
alpha enzyme (additional file 1) a mean IC50 of 660 nM
was determined for QAP 1.
QAP 1 Inhibits Topoisomerase II Alpha and Beta Isoforms 
in a Cell Free Assay
In mammals two topoisomerase II isoforms exist, topoi-
somerase II alpha and beta. The alpha isozyme is
expressed in a cell-cycle regulated manner with highest
levels of expression in G2/M. Topoisomerase II beta is
expressed constitutively in differentiated and in proliferat-
ing cells. Although mouse knockout studies have demon-
strated that topoisomerase II alpha but not beta is
essential for cell proliferation [28,29], recent siRNA data
suggest that the beta isoform can compensate when alpha
is depleted in certain tumor cells [30]. In agreement with
these findings, we have detected an antiproliferative effect
and induction of polyploidy only after depletion of both
topoisomerase II isoforms using RNAi in HeLa cells (data
not shown). However, the proposed partial compensation
by the beta isoform does not occur in all cancer cell set-
tings [31] and could also be attributable to insufficient
enzyme depletion in the alpha knockdown experiments.
Nonetheless, the fact that partial compensation might
arise should be taken into consideration for drug discov-
ery efforts; that is for cancer therapy with catalytic inhibi-
tors, inhibition of both isoforms may be required.
Concurrent inhibition of topoisomerase II alpha and beta
should be achievable with ATP-competitive catalytic
inhibitors as the ATPase domains display a high degree of
homology. To ensure that the purine scaffold targeted
both topoisomerase II isoforms the biotinylated substi-
tuted purine analogue 2 was incubated with HL-60
Table 1: Kinase selectivity profiling of QAP 1 in radiometric filter 
binding assays
Kinase IC50 (μM) Kinase IC50 (μM)
HER-1 > 10 FGFR3-K560E > 10
KDR > 10 Axl > 10
Flt-3 > 10 Fak > 10
IGF-1R > 10 c-Abl > 10
Tek > 10 c-Abl-T315I > 10
c-Src 1.7 ± 0.5 PKA > 10
c-Met > 10 CDK1/CycB > 10
Ret 1.35 ± 0.05 PKB > 10
Jak2 > 10 PDK1 > 10
EphB4 > 10 BRAF-V600E > 10
QAP 1 was profiled against a panel of serine/threonine/tyrosine 
protein kinases. Data typically represent means of two independent 
experiments ± SD.BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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nuclear extracts. Using the biotinylated substituted purine
analogue 2 it was possible to pull down topoisomerase II
alpha and beta isoforms (Figures 2A, B). The interaction
was lost when the nuclear extracts were incubated with an
excess of non-biotinylated parent compound, purine ana-
logue 3 (manuscripts in preparation) but not when incu-
bated with an excess of the substituted purine analogue 4
that was inactive in the ATPase assays (Figure 2B). Impor-
tantly, the interaction of biotinylated purine analogue 2
with both topoisomerase II alpha and beta isoforms was
abolished when QAP 1 was incubated in excess or at equi-
molar concentrations (Figure 2C).
Identification of QAP 1 as an ATP-competitive catalytic inhibitor of topoisomerase II Figure 1
Identification of QAP 1 as an ATP-competitive catalytic inhibitor of topoisomerase II. (A) Chemical structure of 
the substituted purine analogue QAP 1. (B) Concentration-dependent inhibition of topoisomerase II ATPase activity by QAP 1. 
(C, D) Kinetic analysis of DNA-dependent topoisomerase II ATPase activity with vehicle or QAP 1 (130 nM) showing product 
formation in dependence of substrate concentration (C) and Eadie-Hofstee plot (D). (E) Plot representing the IC50s deter-
mined in the presence of different ATP concentrations. (F) Inhibition of topoisomerase II-mediated DNA decatenation in vitro 
by QAP 1 as compared to ICRF-193. Assays were carried out with topoisomerase II from nuclear extracts (NE). The arrow 
marks the position of catenated kDNA substrate and the arrowheads designate the positions of decatenated kDNA topoi-
somerase II products, nicked circular and closed circular minicircles, respectively. (G) IC50 determination of the inhibition of 
DNA decatenation by QAP 1 and ICRF-193, respectively.BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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QAP 1 displays Catalytic Topoisomerase II Inhibition in a 
Quantitative Cell-Based Assay
Although the enzymatic and biochemical cell free experi-
ments show that QAP 1 is a catalytic inhibitor of topoi-
somerase II-mediated DNA decatenation and targets both
enzyme isoforms it is important to assess if the compound
can inhibit topoisomerase II in the cellular context. If cells
are pretreated with catalytic topoisomerase II inhibitors
the amount of active enzyme on chromatin is sharply
reduced. It is by this mechanism that catalytic inhibitors
are thought to antagonize subsequent treatment with
topoisomerase II poisons [32]. DNA damage in the form
of double strand breaks is recognized by cellular surveil-
lance mechanisms and "tagged" at the sites surrounding
the break by posttranslational modification of histone
H2AX in the form of Ser139 phosphorylation (γH2AX)
[33]. In a first step, it was confirmed that the DNA damage
readout (γH2AX) induced by doxorubicin was suppressed
by pretreatment of cells with the catalytic inhibitor tool
compound ICRF-193 (Figure 3A). Next, we corroborated
that the induction of γH2AX by doxorubicin was strictly
dependent on the target protein. Since both topoisomer-
ase II isoforms contribute to DNA damage elicited by
anthracyclines [27], HeLa cells were transfected either
with control siRNA or co-transfected with topoisomerase
II alpha and beta siRNAs. After an incubation period of 72
hours the cells were treated with doxorubicin for two
hours and then extracted for analysis of histones by West-
Cell-free topoisomerase II alpha and beta interaction studies with substituted purine analogues Figure 2
Cell-free topoisomerase II alpha and beta interaction studies with substituted purine analogues. (A) Chemical 
structures of biotinylated purine analogue 2 (compound (cpd) 2), purine analogues 3 (cpd 3) and 4 (cpd 4), respectively. (B) 
Binding of both topoisomerase II alpha and beta to 1 μM biotinylated purine analogue 1 and disruption of binding by parent 
compound 3 but not ATPase inactive compound 4 (both at 10 μM). (C) Binding of topoisomerase II alpha and beta to 1 μM 
biotinylated compound 1 is abolished by 10 fold molar excess and equimolar concentrations of QAP 1.BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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ern blotting. In cells depleted of both isoforms the induc-
tion of γH2AX signal by doxorubicin was substantially
blunted, demonstrating that the DNA-double strand
breaks created by this drug in this experimental setting
require topoisomerase II (Figure 3B). Thus, the γH2AX
readout can be used to profile novel catalytic inhibitors of
Assessment of catalytic topoisomerase II inhibitor relative cellular potency Figure 3
Assessment of catalytic topoisomerase II inhibitor relative cellular potency. (A) Catalytic inhibition of topoisomer-
ase II by ICRF-193 prevents induction of DNA damage by doxorubicin in HL-60 cells as assessed by γH2AX Western blotting. 
Histone H3 levels are shown as loading control. Both drugs were incubated at 5 μM. Cells were pretreated with ICRF-193 for 
30 minutes prior to addition of doxorubicin for 2 hours. (B) Induction of γH2AX by doxorubicin (5 μM, 2 hours treatment) is 
abolished in HeLa cells in which topoisomerase II alpha and beta have been depleted by siRNA. Histone H3 levels are shown as 
loading control in the Western blots. (C) Representative examples of the γH2AX in-cell western assay in 96 well format show-
ing suppression of doxorubicin-induced γH2AX signal by increasing concentrations of ICRF-193 and QAP 1, respectively. Con-
trol designates non-specific γH2AX signal detected in wells where primary antibody was omitted to correct for background. 
TO-PRO was used to normalize for cell numbers. (D) IC50 determination of the inhibition of doxorubicin-induced γH2AX sig-
nal by QAP 1 and ICRF-193, respectively.BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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topoisomerase II for cellular activity and to assess relative
potency. In order to extend the method for higher
throughput and a quantifiable format we adapted the
assay to In Cell Western in 96 well plates [34]. Cells were
treated with increasing concentrations of either ICRF-193
or QAP 1 for 2.5 hours or pretreated with the same dose
range of either drug for 30 minutes prior to addition of 1
μM doxorubicin for 2 hours. Cells were fixed, stained and
then the γH2AX and TO-PRO signals were detected and
quantified with the Odyssey reader. ICRF-193 suppressed
the doxorubicin-induced γH2AX signal with a mean IC50
in the range of 0.2 μM (SD ± 0.11 μM, n = 3) and QAP 1
displayed an IC50 value in the range of 1.1 μM (SD ± 0.07
μM, n = 2) (Figure 3C, D). Neither catalytic inhibitor elic-
ited detectable γH2AX induction by itself using this assay,
as assessed by comparing γH2AX signals with the signals
in DMSO treatment controls. However, we cannot rule
out that detection of subtle DNA damage in the form of
few DNA double strand breaks per cell is missed in the In
Cell Western assay, as several groups have reported that
bisdioxopiperazines can damage DNA [35,36] and high
concentrations of ICRF-193 were shown to induce γH2AX
foci [37]. Taken together, QAP 1 targets topoisomerase II
in cells, however, the drug is less potent in the cellular
context as compared to ICRF-193.
Perturbation of Chromosome Segregation by QAP 1 in a 
Functional Cellular Assay
Early work in yeast demonstrated that topoisomerase II
function is essential at the time of mitosis for chromo-
some segregation [38,39]. To assess if topoisomerase II
inhibition by QAP 1 qualitatively resulted in aberrant
chromosome segregation in cells, spreads were prepared
at the time of mitosis. HL-60 cells were synchronized to
the G1/S boundary by aphidicolin treatment and released
into fresh medium. After 6 hours most cells had entered
the G2 phase and mitosis was occurring by 8 hours as
assessed by FACS analysis and measuring the mitotic
index (data not shown). As a first step, ICRF-193 was used
to monitor the consequences of topoisomerase II inhibi-
tion in this cellular system. When cells had been released
for 6 hours and then treated with 1 μM ICRF-193 and caf-
feine (to override the DNA decatenation checkpoint) for
2 hours no normal anaphases or telophases could be
observed (data not shown), indicating that the catalytic
topoisomerase II inhibitor had prevented DNA decatena-
tion and timely normal chromosome segregation. This is
seemingly consistent with recent evidence showing that
topoisomerase II depletion or ICRF-193 treatment can
delay cells in metaphase up to several hours in a Mad2
dependent manner before they attempt cytokinesis
[15,16]. However, at lower concentrations of ICRF-193
(400 nM) cells could be identified that had progressed
beyond metaphase and anaphase. In the absence of a
more detailed mechanistic understanding of the Mad2-
dependent topoisomerase II metaphase checkpoint we
can only speculate that this checkpoint might be leaky in
HL-60 cells, allowing slippage and progression into ana-
phase despite compromised topoisomerase II function.
Alternatively, checkpoint activation might require levels
of catenated DNA in mitosis to exceed a certain threshold,
since cells normally enter mitosis with residual sister chro-
matid catenations that are only resolved at the time of
metaphase to anaphase transition [40] and during ana-
phase [41]. In the presence of low ICRF-193 concentra-
tions anaphases looked abnormal whereas in control
treated cells two separating groups of chromatin were
readily observable (cf. Figure 4A, B panels 6). Presumably
the abnormal anaphases are the consequence of anaphase
bridging due to incomplete DNA decatenation. Cells were
detected that successfully managed to progress to telo-
phase as seen by the reconstitution of two adjacent nuclei
containing decondensing DNA without detectable signs
of chromosome-bridging (Figure 4B panel 8) but some
cells also displayed obvious signs of chromosome miss-
segregation (Figure 4B panel 7) and cells were observed
that failed entirely to segregate their chromosomes and
reconstituted tetraploid nuclei (Figure 4B panels 9, 10).
Importantly, when cells were treated in G2 with 10 μM
QAP 1 mitosis was also severely perturbed during ana-
phase, which is consistent with topoisomerase II inhibi-
tion (Figure 4C). Furthermore, although sister chromatid
resolution occurred, metaphase chromosomes in QAP 1
treated cells consistently appeared slightly less condensed
as compared to control treated cells (cf. Figure 4A, C pan-
els 5). This latter finding is in agreement with topoisomer-
ase II depletion studies and with earlier work using
bisdioxopiperazines that imply a role for topoisomerase II
in the final compaction of chromosomes [30,31]. We
believe that the concentrations of ICRF-193 and QAP 1
that evidently perturbed mitotic progression at anaphase
and beyond relate relatively well with intracellular target
inhibition and ensuing antiproliferative effects. Indeed, in
proliferation assays over 72 hours the half-maximal
growth inhibitory concentration (GI50) was determined
as 250 nM for ICRF-193 and 8 μM for QAP 1 in HL-60
cells.
BRCA1 Mutant Breast Cancer Cells Display Increased 
Sensitivity to both Non-ATP-Competitive and ATP-
Competitive Catalytic Topoisomerase II Inhibition
Given the findings that QAP 1 targets topoisomerase II
catalytic function in cells we explored the action of the
drug in a model of BRCA1 mutation. It has previously
been shown that G2 DNA decatenation checkpoint defi-
ciency can confer hypersensitivity to the catalytic topoi-
somerase II inhibitor ICRF-193 [13] and that ATR/BRCA1
are required to enforce this checkpoint [12]. BRCA1
mutant HCC1937 breast cancer cells were previously
shown to be deficient in the DNA decatenation check-BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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Analysis of chromosome segregation in HL-60 cells by chromosome spreading Figure 4
Analysis of chromosome segregation in HL-60 cells by chromosome spreading. HL-60 cells were synchronized to 
the G1/S boundary by aphidicolin treatment for 16 hours and then released into fresh medium. After 6 hours release, the cells 
were treated as indicated below for 2 hours prior to preparation of chromosome spreads. (A) Cells treated with DMSO vehi-
cle and 1 mM caffeine. (B) Cells treated with 400 nM ICRF-193 and 1 mM caffeine. (C) Cells treated with 10 μM QAP 1 and 1 
mM caffeine. The following mitotic stages are shown: Late G2 (A1, B1 and C1), early prophase (A2, B2 and C2), prophase (A3, 
B3 and C3), prometaphase (A4, B4 and C4), metaphase (A5, B5 and C5), anaphase (A6, A7, B6, C6 and C7), telophase (A8–10, 
B7–B10 and C8–C10). Note, that each image represents a different cell. Arrows depict cells with evidence of chromosome 
malsegregation, arrow head depicts anaphase bridging.BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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point and that this checkpoint is restored in HCC1937
cells with reconstituted wild type BRCA1 expression [12].
In addition, BRCA1 appears to be important for regulating
topoisomerase II DNA decatenation activity [42]. The
effects of ICRF-193 and QAP 1 on BRCA1 mutant and
BRCA1 reconstituted HCC1937 cells were assessed in clo-
nogenic growth assays. Immunoprecipitation and West-
ern blotting with a combination of different BRCA1
antibodies was used to confirm that the HCC1937 cells
expressed mutant carboxyl-terminally truncated BRCA1
and that the BRCA1 reconstituted HCC1937 expressed the
full-length protein (Figure 5A). Analysis of nuclear
extracts revealed that both cell lines expressed comparable
levels of topoisomerase II alpha and beta (Figure 5A). In
clonogenic growth assays, we observed that BRCA1
mutated cells were somewhat more sensitive towards
ICRF-193 as determined by measuring relative prolifera-
tion using the WST-1 reagent, a tetrazolium salt that is
cleaved in mitochondria of metabolically active cells, and
by counting colony numbers after crystal violet staining
(Figure 5B). Encouragingly, QAP 1 also displayed a differ-
ential antiproliferative effect on BRCA1 mutant versus
BRCA1 reconstituted cells and this effect was most evident
at a concentration of 5 μM (Figure 5C). At this dose of the
compound a striking suppression of colony formation of
BRCA1 mutant cells was seen. In contrast, the Hsp90
inhibitor 17-AAG affected growth of BRCA1 mutant and
BRCA1 reconstituted cells to a similar extent (Figure 5D),
suggesting that the effects seen with the catalytic topoi-
somerase II inhibitors were not due to a general hypersen-
sitivity of BRCA1 mutant cells towards anti-proliferative
agents.
Discussion
The novel rationally designed purine analogue QAP 1 was
found to inhibit human topoisomerase II DNA-depend-
ent ATPase activity and DNA decatenation in vitro with
submicromolar IC50s and to inhibit the enzyme with an
ATP-competitive mode of action. Although purine ana-
logues have recently been described as catalytic inhibitors
of topoisomerase II [21,22], to our best knowledge QAP 1
represents the most potent and selective example of this
chemotype described to date. Interestingly, topoisomer-
ase II dimers consisting of one wild-type and one ATPase
dead molecule have been found to still be capable of car-
rying out DNA strand passage reactions in vitro [43]. This
suggests that ATP-competitive inhibitors may need to
attain intracellular concentrations that saturate both ATP-
binding sites of the topoisomerase II dimer for efficient
inhibition of DNA decatenation, whereas a single bisdiox-
opiperazine molecule binds and bridges the ATP-associ-
ated dimer molecules [18].
In vitro QAP 1 displayed greater than 10 fold selectivity
over a standard panel of kinases, although some inhibi-
tion of the Ret and Src tyrosine kinases was observed. Fur-
ther optimization will be required to reach low
nanomolar potency toward topoisomerase II while
improving selectivity over kinases. The recently described
crystal structure of the human topoisomerase II ATPase
domain is expected to aid such drug discovery efforts [23];
co-crystallization with purine scaffolds will be crucial to
corroborate binding mode and provide further impetus
for lead optimization.
Cellular activity of QAP 1 was demonstrated by antago-
nism of topoisomerase II poison-induced DNA damage
and aberrant chromosome segregation, even though
ICRF-193 was more potent in both of these assays. On the
other hand, in the clonogenic growth assays QAP 1 and
ICRF-193 affected BRCA1 mutant cells to a comparable
extent at a concentration of 5 μM. Although the bisdioxo-
piperazine class catalytic inhibitors of topoisomerase II
are used for the treatment of adult T-cell leukemia in
Japan, their use in other cancer indications has been lim-
ited to the modulation of anthracycline-related cardiotox-
icity [9]. A key issue in the development of catalytic
inhibitors of topoisomerase II is that, although the
enzyme is clearly druggable, it is currently not obvious
which tumors bearing which kind of molecular altera-
tions will respond particularly well to such drugs and
what the effects on normal cells and stem cells will be
[44]. It is anticipated that catalytic inhibitors will show
less side effects compared to topoisomerase II poisons but
will also display a narrower anti-tumor spectrum. Impor-
tantly, concepts for exploiting the anti-proliferative activ-
ity of catalytic topoisomerase II inhibitors based on
molecular characteristics of the tumor cell have recently
started to emerge [13]. The discovery of checkpoint mech-
anisms in G2 and M phase that appear to protect cells tran-
siently from progressing into and through mitosis in the
absence of catalytic topoisomerase II function is a prom-
ising starting point [12,15,16]. The finding that BRCA1
mutant cells displayed slightly increased sensitivity to
QAP 1 supports a role of the protein in the response to cat-
alytic topoisomerase II inhibition. Interestingly, BRCA1
appears to have a dual link to topoisomerase II in that it is
required (i) to enforce the DNA decatenation checkpoint
and (ii) to directly regulate topoisomerase II activity by
ubiquitination [12,42]. Takahashi and colleagues have
observed remarkable hypersensitivity of a subset of lung
cancer cells to ICRF-193. The hypersensitive cell lines
lacked DNA decatenation checkpoint function and
appeared to have impaired ATM activation in response to
ICRF-193 treatment [13]. However, these cannot be the
only criteria since it was found that overriding the DNA
decatenation checkpoint with caffeine was not sufficient
to render non-sensitive cells hypersensitive to the catalytic
inhibitor [13]. Thus, more research will be required to
unravel the molecular alterations predictive of a particu-BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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BRCA1 mutant HCC1937 cells display increased sensitivity to catalytic topoisomerase II inhibition by ICRF-193 and QAP 1 Figure 5
BRCA1 mutant HCC1937 cells display increased sensitivity to catalytic topoisomerase II inhibition by ICRF-
193 and QAP 1. (A) Left panel shows the immunoprecipitation (IP) of BRCA1 from HCC1937 BRCA1 mutant and HCC1937 
BRCA1 reconstituted cells using an antibody that recognizes an internal epitope. In the Western blot (IB) using an antibody 
directed towards BRCA1 carboxyl-terminus the protein is only detected in IPs from the reconstituted cell line. Right panel: 
Levels of topoisomerase II alpha and beta in nuclear extracts of HCC1937 BRCA1 mutant and HCC1937 BRCA1 reconstituted 
cells. Histone H3 was used as a loading control. (B-D) Assessment of relative proliferation and colony formation in represent-
ative clonogenic growth assays with HCC1937 BRCA1 mutant (grey bars) and HCC1937 BRCA1 reconstituted (white bars) 
cells following continuous treatment for 9 days with ICRF-193, QAP 1 and 17-AAG, respectively.BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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larly good response to catalytic topoisomerase II inhibi-
tors and the ICRF-193 hypersensitive cell lines alluded to
above could be invaluable tools for this purpose. Finally,
given the findings of several groups that bisdioxopipera-
zines can interfere with DNA metabolism and damage
DNA [35-37] and that stem and progenitor cells have an
inefficient decatenation checkpoint [44], it will be impor-
tant to determine the effects of ATP-competitive catalytic
topoisomerase II inhibitors in these settings. The potential
therapeutic value of potent and selective ATP-competitive
inhibitors will also be determined by their impact on non-
tumor cells versus sensitive tumor cells in pre-clinical
models.
Conclusion
In the present study, we describe a novel purine diamine
analogue, termed QAP 1, which emerged from molecular
modeling efforts as a potent catalytic inhibitor of topoi-
somerase II alpha and beta. The inhibitor blocks topoi-
somerase II ATPase and decatenation activity in
biochemical assays and depletes enzyme function in cel-
lular systems. In particular, we show that QAP 1 antago-
nizes anthracycline-mediated DNA damage as assessed by
suppression of γH2AX induction and perturbs chromo-
some segregation. The inhibitor QAP 1 represents a prom-
ising starting point for lead optimization campaigns and
further drug discovery efforts. Importantly, the ATP-com-
petitive catalytic inhibitor also represents a novel tool,
with distinct mechanism of action as compared to bisdi-
oxopiperazines, to assess the effects of topoisomerase II
inhibition in cancer cells and in normal cells. It is the pre-
vailing view that tumor cell sensitivity to catalytic topoi-
somerase II inhibitors may be attributed to cell lineage
and/or specific checkpoint defects. In agreement with pre-
vious analyses, the present study shows that BRCA1
mutant cells display increased sensitivity to catalytic
topoisomerase II inhibitors. However, many questions
remain regarding the checkpoint mechanisms postulated
to monitor DNA topology in G2 and M cell cycle phases,
respectively. ATP-competitive catalytic topoisomerase II
inhibitors such as QAP 1 could be instrumental to screen
tumor cell lines and, combined with genetic as well as
molecular studies, help identify tumor settings with
increased susceptibility.
Methods
Chemical synthesis and reagents
Quinoline aminopurine 1 (QAP 1), biotinylated purine
analogue 2, purine analogues 3 and 4 (detailed synthesis
will be described elsewhere), 17-AAG and ICRF-193 (BIO-
MOL Research Laboratories Inc., Plymouth Meeting, PA)
were dissolved in DMSO to yield 10 mM final concentra-
tion and stored at -20°C. Doxorubicin (BIOMOL
Research Laboratories Inc., Plymouth Meeting, PA) was
dissolved in distilled water to yield 10 mM final concen-
tration and stored at -20°C. All other chemical reagents
were analytical grade quality. All cell culture reagents were
purchased from AMIMED (Allschwil, Switzerland).
Full length tagged human topoisomerase II alpha protein 
production
Human topoisomerase II α cDNA was cloned in three suc-
cessive steps. First the 5' region of the topoisomerase II α
gene upstream of the EcoR1 site was amplified by PCR
using an ATCC clone (#59748) as template and primers
adding a Bgl2 site at its 5' end. The purified PCR product
was digested with Bgl2 and EcoR1 and inserted into
pFastBac1 (Invitrogen, Carlsbad, USA) previously
digested with BamH1 and EcoR1. Then, an EcoR1/Pst1
fragment of the topoisomerase II α ATCC clone was
inserted into the EcoR1/Pst1 sites of the plasmid previ-
ously obtained. Finally, the 3' end of topoisomerase II α
downstream of Pst1 was amplified by a two-step PCR
using the ATCC clone as template and primers adding a
PreScission-His6-Strep tag and a Sph1 site at the 3' end.
This product was subsequently digested with Pst1 and
Sph1 and inserted into the corresponding sites of the plas-
mid previously obtained. The sequence of the inserted
gene and flanking regions was verified by DNA sequenc-
ing. Topoisomerase II α protein was expressed in Sf21
cells (Invitrogen, Carlsbad, USA) using the Baculovirus
system (multiplicity of infection 2.0, 72 h infection). The
cell pellet was resuspended in 15 volumes ice cold lysis
buffer (50 mM Na2HPO4 pH 7.7, 500 mM NaCl, 10 mM
β-mercaptoethanol, 5 mM imidazol, 100 μg/ml PMSF, 2
mM MgCl2  and EDTA-free protease inhibitor cocktail
(Roche Diagnostics GmbH)) and homogenized using a
Heidolph Diax 600 homogenizer. Following centrifuga-
tion for 60 minutes at 48000 g and filtration through a 3
μm Millipore filter the lysate was loaded on a 5 ml His-
Trap HP affinity column (GE Healthcare, Sweden), pre-
equilibrated in buffer A (50 mM Tris-HCl pH 8.0, 500 mM
NaCl, 10 mM β-mercaptoethanol and 5 mM imidazol).
The column was washed with buffer A containing 20 mM
imidazole and the protein was eluted with a gradient of
buffer B (250 mM imidazole in buffer A). Pooled fractions
containing topoisomerase II protein were loaded on a
SPX200 size exclusion column (16/20) equilibrated with
50 mM Tris HCl pH 7.7, 150 mM NaCl and 2 mM DTT,
followed by loading on a 10 ml StrepTactin column (IBA,
Germany) equilibrated with 100 mM Tris HCl pH 8.0,
150 mM NaCl, 2 mM β-mercaptoethanol, 1 mM EDTA.
After a brief washing step, the enzyme was eluted with and
stored in 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM
β-mercaptoethanol, 1 mM EDTA and 2.5 mM desthiobi-
otin. Single-use aliquots of enzyme were flash-frozen in
liquid nitrogen and stored at -80°C until use.
ATPase assay and kinetic analysis
DNA-dependent ATP hydrolysis of human topoisomerase
II α was monitored by measuring the production of inor-
ganic phosphate using acidic molybdate and malachiteBMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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green [45]. Specific ATPase activity of every batch was
tested in a time-course to determine optimal incubation
times and enzyme concentrations within the linear range
of the assay. Reactions thus contained 10 – 40 nM topoi-
somerase II (dimer concentration) in reaction buffer (10
mM Tris HCl pH 7.5, 175 mM KCl, 0.1 mM EDTA, 5 mM
MgCl2, 2 mM DTT, 2.5% glycerol and 1.7 nM supercoiled
pUC18). The specific activity of the human topoisomerase
II α enzyme measured in the ATPase assay was 0.24 μmol
PO4·min-1·mg-1. Compounds were initially screened at
10 μM concentration and IC50 values were determined if
inhibition was greater than 70%. Compounds at the indi-
cated concentrations were added as serial dilutions pre-
pared in DMSO and preincubated for 10 minutes at 37°C
on an orbital shaker. Reactions were started by the addi-
tion of 400 μM ATP (Sigma, catalog number A2383) and
allowed to proceed for 30 minutes. Reactions were termi-
nated by the addition of 200 μl malachite green reagent
and the OD was read immediately at 630 nm on a Spec-
traMax Plus microtiter plate reader using SoftMax Pro soft-
ware (Molecular Devices). For kinetic analysis, reactions
were carried out in duplicate as described above either in
the presence of vehicle (DMSO) or QAP 1. Following a
preincubation for 5 minutes, ATP was added at the indi-
cated concentrations to start the reactions, which were
allowed to proceed for 17 minutes before stopping and
reading as above. From these values the OD values
obtained at each respective ATP concentration without
enzyme were subtracted for background correction. The
low signal to noise ratio of the malachite green assay did
not permit the study of a broad range of inhibitor concen-
trations in competition experiments. Low inhibitor con-
centrations did not result in enough inhibition to clearly
demonstrate the effect of the inhibitor and higher inhibi-
tor concentrations gave very weak signals. A compromise
was found by carrying out the competition experiments
with a single concentration of the inhibitor that gave a
good inhibition of enzyme activity while keeping a meas-
urable signal. The equations used to fit these experiments
are:
Competitive inhibition:
Uncompetitive inhibition:
Mixed inhibition:
Each competition experiment was fitted (Grafit version
5.04 – Erithacus Software) with these 3 equations and the
models that gave unrealistic inhibition constants (above
10 mM) and/or large standard errors (similar to the value
of the fitted parameter) were rejected. Then, the F-test was
carried out to identify the best fitting model. An alterna-
tive method was used to determine the mode of action of
the inhibitor. Dose-response experiments were carried out
at different ATP concentrations and the corresponding
IC50s determined. According to the Cheng-Prusoff equa-
tion for linear competitive inhibition [25]:
The IC50  of a competitive inhibitive inhibitor should
increase in a linear fashion with the concentration of ATP.
The measured IC50s were then plotted in function of the
ATP concentrations and linear regression analyses were
carried out. For calculation of Michaelis-Menten kinetic
parameters [46] data were plotted in XLfit 4 (XLfit 4 curve
fitting software for Microsoft Excel, ID Business Solutions
Ltd, Guildford, Surrey, United Kingdom) and linearized
according to Eadie-Hofstee. In the latter plot data points
obtained at the lowest ATP concentration were omitted as
these are the most error prone. Mean Km and Vmax values
were calculated from two independent experiments.
DNA decatenation assay
Reagents for the assay were purchased from TopoGEN (cat-
alog number 1001–1, TopoGEN, Inc., Port Orange, FL).
Topoisomerase II was extracted according to the manufac-
turer's instructions from nuclei of HL-60 cells (ATCC;
American Type Culture Collection, Manassas, Virginia,
USA) and contained both isoforms as assessed by Western
blotting. Calculation of specific topoisomerase II decatena-
tion activity was based on complete decatenation of a given
amount of catenated input DNA (100 ng kDNA) by a
defined amount of nuclear extract containing the alpha and
beta isoforms or of a defined amount of purified enzyme in
a particular amount of time. The topoisomerase II activity
from nuclei decatenated 0.07 ng catenated kDNA · min-1 ·
ng-1 extract. Purified topoisomerase II alpha (see above)
decatenated 0.13 ng catenated kDNA · min-1 · ng-1. Vehicle
(DMSO) or drug substance at concentrations to yield the
desired end concentrations were added and samples were
preincubated for 5 minutes at 37°C and 400 rpm in an
Eppendorf thermomixer. Reactions were started by adding
ATP (to 450 μM final concentration) to each sample and
incubation was continued for 20 minutes. Reactions were
v
VS
Km
I
KiS
S
=
++
max.[ ]
.(
[]
)[] 1
v
VS
Km S
I
KiI
=
++
max.[ ]
[] . (
[]
) 1
v
VS
Km
I
KiS
S
I
KiI
=
+++
max.[ ]
.(
[]
)[] . (
[]
) 11
IC K
ATP
Km
i 50 1 =+ (
[]
)BMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
Page 13 of 16
(page number not for citation purposes)
terminated by placing the samples on ice and adding 4 μl
stop/gel loading buffer. 20 μl of each sample were sepa-
rated by 1% agarose gel electrophoresis. Gels were analyzed
under a UV transilluminator and decatenated kDNA prod-
ucts were quantified using AlphaEaseFC (FluorChem
8900) image analysis software version 3.2.3 (Alpha
Innotech, San Leandro, CA).
Affinity precipitation
Topoisomerase II α and β were affinity precipitated with
biotinylated inhibitor as follows. Exponentially growing
HL-60 cells were collected on ice and incubated with
hypotonic buffer (10 mM HEPES pH 7.5, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF, 1× protease
inhibitor cocktail (Complete Mini, Roche Diagnostics
GmbH)) for 15 minutes, then 0.6% v/v NP-40 was added
and cells were disrupted using a Dounce homogenizer.
Lysates were transferred to 1.5 ml Protein LoBind Eppen-
dorf tubes and nuclei were collected after centrifugation at
8000 rpm for 10 minutes and washed twice with hypot-
onic buffer. To extract and release chromatin associated
topoisomerase II nuclei were incubated for 30 minutes in
DNAse buffer (20 mM Tris HCl pH 7.5, 5 mM MgCl2, 1
mM CaCl2, 25 mM NaCl, 0.5 mM EDTA, 1% NP-40, 1
mM DTT, 1 × protease inhibitor cocktail, 0.1 mM PMSF)
containing 40 U DNAse I (Roche Diagnostics GmbH) fol-
lowed by addition of twice concentrated nuclear extrac-
tion buffer (20 mM HEPES pH 7.5, 3 mM MgCl2, 20 mM
KCl, 50 mM β-glycerophosphate, 840 mM NaCl, 1 mM
EDTA, 50 mM PNPP, 1 mM DTT, 1 mM PMSF) and rota-
tion for 1 h in the coldroom. The soluble fraction was
obtained following centrifugation at 13000 rpm for 15
minutes. 25 μg nuclear extract were used for the affinity
precipitation. The salt concentration was adjusted to 150
mM with nuclear extraction buffer (without NaCl) and
the sample volume was toped off to 200 μl with precipita-
tion buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 25 mM
β-glycerophosphate, 25 mM NaF, 5 mM EGTA, 1 mM
EDTA, 15 mM PPI, 1 mM PMSF). Compounds were pre-
incubated for 30 minutes prior addition of biotinylated
purine analogue 2 for 2 h. Streptavidin agarose beads
(Novagen, 69203) were washed twice with PBS, blocked
for 30 minutes with PBS containing 1% BSA, washed
twice with PBS and finally with precipitation buffer. 40 μl
equilibrated streptavidin agarose beads were added to the
sample and incubation was continued for 1 h. Beads were
pelleted by centrifugation at 7000 rpm for 5 minutes and
washed thrice with precipitation buffer. During the last
wash the beads were transferred to a new tube and the
bound fraction was released by boiling for 5 minutes in
Laemmli sample buffer. Topoisomerase II α and β were
detected by Western blot as described below.
Topoisomerase II α and β siRNA
0.3 × 106 HeLa T-Rex cells (Invitrogen, Paisley, United
Kingdom UK) per 6-cm plate were seeded in 2.6 ml of
medium without antibiotics. The day after seeding, cells
were transfected for 72 hours with stealth RNA oligos
(Invitrogen, Paisley, United Kingdom UK): stealth control
oligo 1: 5'ACUUCCGAUUCGUGUAACCGAC UUU3';
and stealth control oligo 2: 5'GGGCUA
GUUAUAGUCGACACUGGUA3') or with stealth RNA
oligos directed against topoisomerase II α and β tran-
scripts (α1: 5'ACUCAGCCUCUUAUGUGCCAAGUUU3';
α2: GGACAACAUUUG AUCCAAGAUCUUA3' and β1:
5'GGGUGAUCUUGAUACUGCAGCAGUA3'). Lipo-
fectamine™ 2000 was used to transfect oligos according to
the manufacturer's instructions. Lipofectamine contain-
ing medium was replaced 6 hours after transfection by 3
ml of fresh culture medium. Cells were extracted in 200 μl
lysis buffer (50 mM Tris-HCl, pH 7.5; 5 mM EDTA; 420
mM NaCl; 0.5% Nonidet P-40 (NP-40); 1 mM Benzami-
dine; 20 mM NaF and 1.5 mM MgCl2) freshly supple-
mented with 1 mM PMSF (from 100 mM stock solution
in ethanol), 1 mM DTT (from 1 M stock solution) and 1×
protease inhibitor cocktail. Lysates were centrifuged at
maximum speed in an Eppendorf centrifuge for 10 min-
utes at 4°C. The nuclear pellet was resuspended in 22 μl
of Laemmli sample buffer and boiled at 95°C for 5 min-
utes. 15 μl of nuclear extracts were subjected to 6% dena-
turing SDS-PAGE, transferred to PVDF membranes and
probed with the anti-topoisomerase II β antibody (sc-
13059, Santa Cruz Biotechnology, Santa Cruz, CA; diluted
1:1000 in PBS 0.1% Tween) using appropriate secondary
antibody and enhanced chemiluminescence (ECL, Amer-
sham Pharmacia Biotech Inc., Buckinghamshire, United
Kingdom). After stripping the membrane it was re-probed
with a goat anti-topoisomerase II α antibody (sc-5348,
Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:2000
in PBS 0.1% Tween). Immunoreactive bands were
revealed by HRP-conjugated protein G (Zymed, CA;
diluted 1:3000 in PBS 0.1% Tween) using ECL reagents.
Gamma-H2AX assay
Histone extracts of HL-60 or HeLa T-Rex cells for Western
blot analysis were prepared as follows: Following treat-
ments, medium was removed and cells were collected/
washed with PBS. Cells were centrifuged for 5 minutes at
1500 rpm and 4°C and the cell pellet was resuspended in
300 μl of ice-cold hypotonic buffer (see above). Cells were
transferred in a 1.5 ml Eppendorf tube and incubated for
15 minutes on ice. Thereafter, NP-40 was added to the
cells to a final concentration of 0.6% (v/v) and cells were
disrupted by pumping 10–15 times through a 1 ml
syringe connected to a 23-gauge needle. The extract was
centrifuged for 10 minutes at 8000 rpm and 4°C. The
supernatant (cytoplasmic fraction) was removed and the
nuclear pellet was washed once with 500 μl of ice-cold
hypotonic buffer for 4 minutes at 8000 rpm. Nuclear pro-
teins were extracted by addition of 22 μl sample buffer
and boiling for 3 minutes. Samples were resolved by 15%
SDS-PAGE following transfer to PVDF membrane. AfterBMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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blocking, membranes were incubated either with anti-
γH2AX (clone JBW301, 05–636, Upstate, Charlottesville,
VA, diluted 1:1000 in PBS containing 0.1% Tween 20 and
5% milk) or histone H3 (catalog number 9715, Cell Sign-
aling Technologies Inc., Beverly, MA, diluted 1:1000 in
TBS containing 0.1% Tween 20 and 5% milk) antibodies
overnight at 4°C. The corresponding horseradish peroxi-
dase conjugated secondary antibodies were diluted
1:3000 and incubated for 1 hour at room temperature and
immunoreactive bands were revealed as described above.
In-Cell Western analysis was carried out as follows. HeLa
T-Rex cells were seeded at the cell density of 15 × 103 cells
per well in black 96-well plates (Greiner Bio-one Vacu-
ette, St Gallen, Switzerland). The day post-seeding, cells
were pretreated with increasing concentrations of either
ICRF-193, QAP 1 or vehicle (DMSO) for 30 minutes fol-
lowed by a 2 hours treatment with 1 μM of doxorubicin,
or were only treated with the same concentrations of
ICRF-193, QAP 1 or vehicle (DMSO) for 2 hours. Treat-
ments were done in triplicate. Cells were directly fixed by
adding 100 μl of 3.7% formaldehyde (diluted 1:10 in
PBS from a 37% formaldehyde solution; Sigma, Buchs,
Switzerland) per well for 10 minutes at room tempera-
ture. Cell membranes were permeabilized by 4 washes
with 100 μl per well of PBS containing 0.25% Tween-20
for 4 minutes. Cells were blocked with 50 μl per well of
Odyssey Blocking Buffer (OBB; LI-COR Biosciences
GmbH, Bad Homburg, Germany) for 2 hours at room
temperature with gentle agitation. 25 μl per well of
γH2AX antibody (clone JBW301, catalogue number 05–
636, Upstate, NY) diluted 1:500 in OBB were incubated
overnight at room temperature with gentle agitation.
Cells were washed 5 times with 50 μl per well of PBS con-
taining 0.1% Tween-20 for 3 minutes and stained with
25 μl per well of goat anti-mouse InfraRedDye 800 anti-
body (Rocklands Immunochemicals, Inc., Gilbertsville,
PA) diluted 1:800 in OBB containing 0.2% Tween-20 for
1 hour at room temperature in the dark. An additional
wash with 50 μl per well of PBS containing 0.1% Tween-
20 was performed before DNA staining with 50 μl per
well of TO-PRO-3 iodide (642/661) (Invitrogen AG,
Basel, Switzerland) diluted 1:5000 in OBB for 1 hour at
room temperature in the dark. Finally, cells were washed
4 times with 50 μl per well of PBS containing 0.1%
Tween-20 for 3 minutes, liquid was removed and plates
were kept at 4°C until reading. γH2AX signals were read
using the LI-COR Odyssey Infrared Imager with the
Odyssey v1.1 software using the 800 nm channel. Blank
values correspond to non-specific γH2AX signal detected
in wells without primary antibody staining. The means
of these values were subtracted from the γH2AX signals
to correct for non-specific background. The resulting val-
ues for each sample were normalized to the DNA quan-
tity by measuring the corresponding TO-PRO-3 iodide
signals. The TO-PRO-3 iodine signals were detected by
using the 700 nm channel. The percentage of γH2AX sig-
nal was determined for each concentration of ICRF193
and QAP 1 with or without doxorubicin treatment by
setting the value for the treatment with vehicle and 1 μM
doxorubicin to 100%. To display relative suppression of
γH2AX induction and catalytic topoisomerase II inhibi-
tion in cells the values measured in the presence of cata-
lytic inhibitor were subtracted from the corresponding
value measured at the same concentration of catalytic
inhibitor but in the presence of 1 μM doxorubicin. These
data were plotted in XLfit 4 (XLfit 4 curve fitting software
for Microsoft Excel, ID Business Solutions Ltd, Guild-
ford, Surrey, United Kingdom) to determine the IC50 val-
ues of the catalytic topoisomerase II inhibitors by using
four parameter logistic calculation.
Chromosome segregation assay
HL-60 cells were treated overnight for 16 hours with 2 μg/
ml aphidicolin (Sigma-Aldrich corporation, St. Louis,
MO) and released by washing twice PBS and resuspending
into fresh medium. After 6 hours release the cells were
treated with 1 mM caffeine (Lancaster Synthesis, Hey-
sham, Lancashire, UK) and with catalytic topoisomerase II
inhibitor or vehicle for 2 hours. Cells were washed once
with PBS and incubated with 56 mM KCl hypotonic solu-
tion for 30 minutes. Cells were pelleted and carefully
resuspended in Carnoy's fixative. Cells were pelleted as
above, supernatant was removed and cells were resus-
pended again in 2 ml fixative. Chromosome spreads were
prepared by dropping 50 μl cell suspension onto micros-
copy slides. The slides were allowed to dry and then
stained for 10 seconds in Hoechst 33342 dye (Molecular
Probes, Eugene, Oregon, prepared 1:1000 in PBS from 10
mg/ml stock). After drying, mounting media (Vectash-
ield®, Vector Laboratories, Burlingame, CA) and a cover
slip were added. Samples were observed using an immer-
sion oil lens (100 ×, Nikon, Plan Apo VC) by fluorescence
microscopy (Nikon Eclipse, E600) in the DAPI channel.
Images were acquired using analySIS® software (Soft Imag-
ing System GmbH, Münster, Germany). Representative
images were converted to grayscale, inverted and contrast
adjusted with Adobe Photoshop. Mitotic cells were cate-
gorized as described [47].
Clonogenic growth assay with HCC1937 cells
HCC1937 BRCA1 mutant and HCC1937 BRCA1 recon-
stituted breast ductal carcinoma cells were cultured in
RPMI-1640 medium supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 4.5
g/l glucose and 1% (v/v) penicillin/streptomycin. Status
of BRCA1 was corroborated by immunoprecipitation
using 50 μg nuclear extracts and 1 μg mouse monoclonal
antibody MS110 (ab16780, Abcam Inc., Cambridge,
MA), which is directed towards the amino-terminus ofBMC Chemical Biology 2009, 9:1 http://www.biomedcentral.com/1472-6769/9/1
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the protein. Blots were probed with BRCA1 carboxy-ter-
minal specific mouse monoclonal antibody D9 (sc-
6954, Santa Cruz Biotechnologies, Santa Cruz, CA) and,
following stripping, re-probed with antibody MS110.
For assays, 5000 cells in 3 ml medium were seeded per
well of 6 well plates in duplicates. The day after, vehicle
(DMSO) or compounds were added. After one week
medium was exchanged and vehicle or compounds were
re-added for an additional two days. To assess prolifera-
tion the medium in each well was replaced with 1 ml
medium containing 100 μl WST-1 reagent and incuba-
tion for 20 minutes at 37°C. Of each sample 110 μl
supernatant were transferred into a 96 well plate and the
OD was read at 450 nm (filter at 630 nm) on a Spec-
traMax Plus microtiter plate reader using SoftMax Pro
software (Molecular Devices). For background correc-
tion, the blank value consisted of 100 μl medium con-
taining 10 μl WST-1. Thereafter, colonies were stained by
removing medium, washing cells once with PBS and
incubation with 1 ml crystal violet solution for 30 min-
utes at room temperature. Cells were washed twice with
PBS and colonies were counted using an Artec Counter
(Model 880, Artec, Dyntatech Laboratories Inc.) with
diameter cut-off set to 0.2 mm. Data were expressed as
growth or colony numbers relative to vehicle control
treatments (100%).
Abbreviations
ATM: ataxia-telangiectasia mutated; ATR: ATM- and Rad3-
related; BRCA1: Breast cancer gene 1; DMSO: Dimethyl
sulfoxide; GHKL: gyrase, Hsp90, histidine kinase, MutL;
IC50 : Half-maximal inhibitory concentration; PBS: Phos-
phate buffered saline; SD: Standard deviation; WRN:
Werner syndrome gene.
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